A proposed preventive role for Gamma-hydroxybutyrate (Xyrem(R)) in Alzheimer's disease.
Gamma-hydroxybutyrate (GHB or Xyrem(R)) is frequently used in humans for several clinical indications, including anesthesia, narcolepsy/cataplexy, and alcohol-withdrawal symptoms. Pharmacological effects induced in the brain by therapeutic doses of Xyrem(R) are generally GABAergic-dependent. These effects allow sedation, stress/anxiety reduction, deep sleep induction, decrease of neuroinflammation, and neuroprotection. Furthermore, Xyrem(R) promotes the expression of pivotal genes reducing toxic proteinopathies, as demonstrated in laboratory animal models. Altogether, these data represent additional evidence to suggest that Xyrem(R) may be tested during repeated short periods in populations at risk for Alzheimer's disease.
Biopathologie de la Myéline, Neuroprotection et Stratégies Thérapeutiques, INSERM U1119, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Bâtiment 3 de la Faculté de Médecine, 11 rue Humann, 67 000, Strasbourg, France. maitre@unistra.fr.
Michel
0000-0003-1478-4806
M
Maitre
Biopathologie de la Myéline, Neuroprotection et Stratégies Thérapeutiques, INSERM U1119, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Bâtiment 3 de la Faculté de Médecine, 11 rue Humann, 67 000, Strasbourg, France.
Christian
C
Klein
Biopathologie de la Myéline, Neuroprotection et Stratégies Thérapeutiques, INSERM U1119, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Bâtiment 3 de la Faculté de Médecine, 11 rue Humann, 67 000, Strasbourg, France.
Ayikoe G
AG
Mensah-Nyagan
D000544:Alzheimer Disease / Q000188:drug therapy*; D000818:Animals; D006801:Humans; D018696:Neuroprotective Agents / Q000008:administration & dosage*; D012978:Sodium Oxybate / Q000008:administration & dosage*
D018696:Neuroprotective Agents; D012978:Sodium Oxybate
Alzheimer’s disease; Gamma-hydroxybutyrate; XyremR; neuroprotection